Consensus Kyverna Therapeutics, Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
12.66 ^USD	-7.25%		-23.78%	0.00%

Apr. 25	Nasdaq's revenue beats on strong demand for fintech products	RE
Mar. 26	Kyverna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

8ba.gh49-3UGJoqd7I2gDkmZ_oUP6_rzEh9K1DOEdmAHB8E.3V93uTFEQuao2c7SbwzQzPVMmY6kJEsyv0X-RBR0WPXTS0--BEJPu-qetQ~390b059ceb7520bfcb62d03e0e0e4030

JPMorgan Initiates Kyverna Therapeutics With Overweight Rating	Mar. 04	MT
Morgan Stanley Starts Kyverna Therapeutics With Overweight Rating	Mar. 04	MT

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.66 USD

Average target price

42.75 USD

Spread / Average Target

+237.68%

High Price Target

48 USD

Spread / Highest target

+279.15%

Low Price Target

39 USD

Spread / Lowest Target

+208.06%

Morgan Stanley
JPMorgan Chase